ACADIA Pharmaceuticals

  www.acadia-pharm.com
  www.acadia-pharm.com

ACADIA Pharmaceuticals Reviews

1 Review
1.0
1 Review

Recommend to a friend
Approve of CEO
ACADIA Pharmaceuticals CEO and Director Uli Hacksell
Uli Hacksell
1 Rating
  1.  

    Acadia - pays ok, but will fire you.

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Former Employee - Research Scientist in Malmö, Skåne (Sweden)
    Former Employee - Research Scientist in Malmö, Skåne (Sweden)

    I worked at ACADIA Pharmaceuticals

    Pros

    Normally a good salary can be obtained. I feel that a good work-private time can be achieved. A fair ammount of freedom can at times be given.

    Cons

    Everything is ruled by one director. Evebn if an attempt is beeing made to solve some difficult issues this attempt, and with it several years of research can be thrown away. Teh people in charge do not look upon the data in a scientific, neutral way. Instead they are bias and take into acount the data that supports their theory.
    The senior management tend to be a little bit too full of themselves.
    Getting fired.

    Advice to ManagementAdvice

    A more modest aproach. Actually sselling or partnering project before moving them into phase 2. One person should not be in charge for the research.

    Doesn't Recommend
    Disapproves of CEO

ACADIA Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.acadia-pharm.com
Headquarters San Diego, CA
Size 16 to 50 Employees
Founded Unknown
Type Company - Public (ACAD)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year

ACADIA Pharmaceuticals develops small molecule drugs for the treatment of central nervous system disorders. The biopharmaceutical company's most advanced compound, pimavanserin, is in clinical trials as a treatment for Parkinson's disease psychosis, which occurs in up to 40% of Parkinson's patients. Two other clinical-stage candidates are being developed in collaboration with Allergan to treat patients with chronic pain (AGN-XX/YY) and glaucoma (AC-262271). A preclinical candidate, AM-831, a compound that holds the potential for a new class of antipsychotic drugs, is being... More

Work at ACADIA Pharmaceuticals? Share Your Experiences

ACADIA Pharmaceuticals

 
Click to Rate
or